Powerpack

Unlock full stockrow access for only $9.90/month and boost yourself as an investor.

  • Full quarterly history

    Every quarter and TTM period we hold, not just the last 12.

  • Analyst estimates

    Three years of forward estimates and dividend forecasts.

  • Unlimited screener

    All results, unlimited saved screens, email when a screen changes.

  • Unlimited Excel

    Full workbooks and screener exports.

  • Unlimited follows

See Powerpack
Screener Weekly Summary Pricing

Amylyx Pharmaceuticals, Inc. (AMLX) vs Kiniksa Pharmaceuticals International, plc (KNSA)

Amylyx Pharmaceuticals, Inc. and Kiniksa Pharmaceuticals International, plc are both Drug Manufacturers Specialty & Generic companies. Kiniksa Pharmaceuticals International, plc is the larger, with a market value of $5.9B against $3.8B — 1.6× the size. Amylyx Pharmaceuticals, Inc. has negative trailing earnings, so its P/E is not meaningful; Kiniksa Pharmaceuticals International, plc trades at 70.2×. Kiniksa Pharmaceuticals International, plc grew revenue faster over the last twelve months: 58.9% against −77.1%. Kiniksa Pharmaceuticals International, plc has the higher net margin (9.59% vs 0.00%) and the higher return on invested capital (48.9% vs 0.00%). Across the 16 metrics below, Kiniksa Pharmaceuticals International, plc leads on 15 and Amylyx Pharmaceuticals, Inc. on 1.

Valuation

Metric AMLX KNSA Drug Manufacturers Specialty & Generic median
P/E n/m 70.17 20.14
P/S 37.53 6.93 2.25
P/B 13.71 8.90 1.90
Price to free cash flow n/m 31.84 16.54
EV/EBITDA n/m 51.93 12.29
EV/Sales 34.68 6.30 2.56
Earnings yield (4.85%) 1.43% (2.99%)
Free cash flow yield (3.99%) 3.14% 0.00%

Profitability

Metric AMLX KNSA Drug Manufacturers Specialty & Generic median
Gross margin (42.65%) 89.82% 53.94%
Operating margin 0.00% 11.92% 0.00%
Net margin 0.00% 9.59% 0.00%
Free cash flow margin 0.00% 21.74% 0.00%
Return on equity (74.73%) 14.04% (0.40%)
Return on assets (66.25%) 10.36% (3.32%)
Return on invested capital 0.00% 48.87% 0.00%

Growth

Metric AMLX KNSA Drug Manufacturers Specialty & Generic median
Revenue growth (TTM) (77.06%) 58.85% 10.01%
EPS growth (last fiscal year) 65.46% 225.00% —
Revenue growth, 5-year CAGR — — 6.74%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric AMLX KNSA Drug Manufacturers Specialty & Generic median
Debt to equity 0.00 0.00 0.05
Current ratio 12.12 3.90 2.31
Net debt to EBITDA 2.00 (5.26) 0.85

Dividend

Metric AMLX KNSA Drug Manufacturers Specialty & Generic median
Dividend yield — — 1.70%
Payout ratio 0.00 0.00 0.00

Size

Metric AMLX KNSA Drug Manufacturers Specialty & Generic median
Market cap 3.78b 5.90b 337.35m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack